Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases

AhR

Aryl hydrocarbon receptor

ASH

alcoholic steatohepatitis

ACLF

acute-on-chronic-liver-failure

ASBT

Apical Sodium-dependent BA Transporter

ALD

alcohol-related liver disease

BT

bacterial translocation

CDCA

chenodeoxy-cholic acid

DAMP

danger-associated molecular patterns

FABP

fatty-acid-binding-protein

FDA

Food and Drug Administration

FGF

fibroblast-growth-factor

FMT

fecal microbial translocation

FOS

fructo-oligo-saccharide

GALT

gut-associated lymphatic tissue

HCC

hepatocellular carcinoma

IBD

inflammatory bowel disease

LBP

lipopolysaccharide-binding-protein

TIPS

transjugular-intrahepatic-portovenous stent

MASLD

metabolic dysfunction-associated steatotic liver disease

NASH

Non-alcoholic steatohepatitis

MAMPs

microbe-associated molecular patterns

NAS

non-alcoholic activity score

PAGl

Phenylacetylglutamine

PAMPs

pathogen-associated molecular pattern

PBC

primary biliary cholangitis

PBT

pathological bacterial translocation

PSC

primary sclerosing cholangitis

RCT

randomized controlled trial

SBP

spontaneous bacterial peritonitis

S/LCFA

short/long-chain fatty acids

TIME

tumor immune-micro-environment

TMA/O

Trimethylamin-N-oxid

留言 (0)

沒有登入
gif